Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/eye.2000.29 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiological imaging of multisystem Langerhans cell histiocytosis in a young child: A rare case report.
Radiol Case Rep
December 2024
Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Langerhans cell histiocytosis (LCH) is a rare clonal disorder of the monocyte-macrophage system. There are 3 distinct types of LCH: multisystem type (MS), single-system multi-site (SS-m), and single-system single-site (SS-s). The disease is most common in young children, especially males.
View Article and Find Full Text PDFThe value of 18F-FDG PET/CT in Langerhans cell histiocytosis.
Ann Nucl Med
March 2024
Department of Nuclear Medicine, The Second Xiangya Hospital, Central South University, 139# Renmin Middle Road Changsha, Changsha, 410011, Hunan, China.
Objective: To investigate the value of 18F-FDG PET/CT in diagnosis and disease evaluation of Langerhans cell histiocytosis (LCH).
Methods: A retrospective analysis of 31 patients with LCH confirmed by histopathology was performed. A systematic analysis of the PET/CT imaging manifestations of LCH was performed, recording patients who were treated and receiving PET/CT for efficacy evaluation.
Children are more likely to develop Langerhans cell histiocytosis (LCH), a rare disorder with an unknown cause. LCH often invades skeletal systems, while it has occasionally been seen in the sternum or ribs. The best course of treatment for single-site, skeletal LCH is yet unknown.
View Article and Find Full Text PDFDabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.
Haematologica
April 2024
University of Cincinnati College of Medicine, Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati.
The standard treatment for Langerhans cell histiocytosis (LCH) is chemotherapy, although the failure rates are high. Since MAP-kinase activating mutations are found in most cases, BRAF- and MEK-inhibitors have been used successfully to treat patients with refractory or relapsed disease. However, data on long-term responses in children are limited and there are no data on the use of these inhibitors as first-line therapy.
View Article and Find Full Text PDFResolution of blood eosinophilia and limited mouth opening after short-term follow-up in a pediatric Langerhans cell histiocytosis case.
Indian J Otolaryngol Head Neck Surg
September 2023
Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School (FMRP/USP), University of São Paulo, Ribeirão Preto, São Paulo Brazil.
Introduction: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia that often affects children, presenting a broad clinical spectrum.
Methods: Here, we report a 13-year-old male Salvadorian patient who was referred presenting a nodular swelling at the mandibular angle region, mildly symptomatic, few weeks ago, which relevantly was associated with limited mouth opening. Intraoral examination was unremarkable.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!